Latest Biotech News

Johnson & Johnson said the FDA granted Priority Review to a supplemental Biologics License Application for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) in adults with recurrent or...

Curium announced it has entered into a definitive agreement to acquire Lantheus for up to $8 billion, combining Curium’s radiopharmaceutical manufacturing network and theranostics pipeline with...

Supernus Pharmaceuticals and Indivior have signed an all-stock, tax-free merger agreement to form a new CNS-focused company. The deal, described as a “merger of equals,” will combine Supernus’...

A clinical trial reported by researchers at CU Anschutz found that an AI-driven automated oxygen delivery system helped hospitalized patients stay within prescribed oxygen ranges for a...

Sophia Genetics reported a 27% year-over-year Q2 revenue increase, driven by growth in U.S. customers and liquid biopsy sales. The company also announced a new collaboration with AstraZeneca to...

QuantHealth secured $45 million in Series B funding to expand its AI platform that simulates clinical trials before patients enroll. The company’s approach aims to predict patient outcomes and...

Personalis reported a 30% year-over-year increase in second-quarter revenue, driven by higher pharma testing services and clinical test growth. The company linked the clinical increase to Medicare...

Novartis said the FDA approved Pluvicto for use alongside hormone therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), widening the eligible population...

GeneDx said it completed a reorganization during Q2 that included layoffs affecting approximately 75 employees. The Gaithersburg, Maryland-based genetic diagnostics company reported improved...

A death following a brain-directed gene-editing therapy administered at Xinhua Hospital in Shanghai has reignited debate over how regulators should oversee first-in-human personalized gene...

Curium agreed to buy Lantheus in a deal valued at up to $8 billion, combining Curium’s global manufacturing and theranostics platform with Lantheus’ U.S. radiodiagnostics footprint. Curium will...

Supernus and Indivior signed an all-stock “merger of equals” to form a new CNS-focused company, combining portfolios across addiction, depression, attention-deficit/hyperactivity disorder, and...

QuantHealth raised $45 million in Series B funding to expand an AI platform that simulates clinical trials before patients enroll and predicts outcomes for pharma sponsors. The company says the...

Personalis reported a 30% year-over-year jump in Q2 revenue, driven by higher pharma testing services and a surge in clinical tests following Medicare reimbursement expansion. The company also...

Sophia Genetics reported Q2 revenue growth alongside a new AstraZeneca collaboration covering companion diagnostics in both solid and hematologic cancers. Sophia said the pact will support...

The FDA expanded Novartis’ Pluvicto label to include patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC), advancing the radioligand earlier in the disease course. The...

Pathos AI signed a large licensing package with China’s Alphamab Oncology for an additional TROP2/HER3 bispecific ADC and separately aligned with AstraZeneca on a protein degrader from...

Amgen discontinued its early-stage obesity candidate AMG-513, leaving the company to reallocate resources and increase pressure on late-stage competitors. The company did not provide detailed...

Gilead said its twice-yearly HIV PrEP injection Yeztugo topped Wall Street expectations as sales exceeded $1 billion for the franchise. In Q2, Yeztugo generated $232 million versus estimates of...

A death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at Xinhua Hospital in Shanghai has reopened debate over how regulators oversee personalized,...